Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PYGM | P11217 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PYGL | P06737 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976426 | 0.91 | PYGM (0.59) | PYGMPYGL | |
| SCHEMBL975483 | 0.87 | PYGM (0.56) | MAPTCYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL978414 | 0.86 | TDP1 (0.54) | MAPTCYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL975453 | 0.81 | HDAC1 (0.56) | — | |
| SCHEMBL974393 | 0.79 | HDAC8 (0.61) | L3MBTL1 | |
| SCHEMBL472749 | 0.77 | — | — | |
| SCHEMBL13845066 | 0.77 | ALDH1A1 (0.49) | L3MBTL1 | |
| SCHEMBL27943418 | 0.77 | MAPT (0.67) | MAPTCYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15464521 | 0.76 | CYP1A2 (0.50) | MAPTCYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL975482 | 0.75 | PYGM (0.58) | MAPTCYP1A2CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| WO-2009055917-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | MAPT 2336/4885CYP1A2 1295/4885CYP2C9 786/4885 |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | MAPT 2336/4885CYP1A2 1295/4885CYP2C9 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.